FDA approves Sanofi’s Infilbray for neurological Type 3 Gaucher disease

On November 18, 2026, the US Food and Drug Administration approved Sanofi’s Infilbray (venglustat) for neurological manifestations of Type 3 Gaucher disease in adults and pediatric patients weighing at least 15 kg. The oral treatment was evaluated against imiglucerase in the LEAP2MONO phase 3 study, which showed statistically significant superiority across neurological measures, with p=0.0137. Sanofi’s release describes Infilbray as the first medicine approved for these neurological manifestations and says it plans additional international filings.

The decision gives Sanofi a US-authorized oral treatment for a rare neurological disease with no previously approved therapy targeting these manifestations. The label includes cautions involving suicidal thoughts or behavior, pediatric lens clouding, and embryo-fetal toxicity, while Sanofi expects to pursue further regulatory submissions.

  • 1The FDA authorized Infilbray for neurological Type 3 Gaucher disease in adults and children weighing at least 15 kg.
  • 2In LEAP2MONO, Infilbray was superior to imiglucerase on the prespecified global neurological assessment, with p=0.0137.
  • 3The product carries US label warnings concerning suicidal ideation and behavior, lens opacification in pediatric patients, and embryofoetal toxicity.
  • 4Sanofi said it will pursue additional GD3 regulatory submissions in 2026 and 2027.

Sources